Egyptian Hypertrophic Cardiomyopathy Program

NCT05884892 | Recruiting DMC

• 1 other identifier: AHC-HCM
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

Egyptian HCM program aims at defining incidence, severity, phenotype, genotype and determinants of the disease in Egypt, and providing state-of-the-art treatment strategies including medical, surgical and interventional procedures which are patient- and disease-specific.

Conditions

Hypertrophic Cardiomyopathy

Keywords

HCM; HOCM; Hypertrophic Cardiomyopathy; Familial Hypertrophic Cardiomyopathy; Hypertrophic Cardiomyopathy with Genetic Marker; Hypertrophic Obstructive Cardiomyopathy

Outcome Measures

Primary Outcomes (5)

• Incidence of HCM in Egypt

  per 100,000 population per year

  through study completion, an average of 5 year

• Determinants of clinical severity of HCM in Egypt

  Several indicators describing the clinical symptoms and signs

  through study completion, an average of 1 follow-up every year, and an average of 5 follow-ups throughout the study duration

• Determinants of cardiac phenotype severity of HCM in Egypt

  Several indicators describing the cardiac phenotype using multimodality imaging

  through study completion, an average of 1 follow-up every year, and an average of 5 follow-ups throughout the study duration

• Determinant of genotype severity of HCM in Egypt

  To identify and report the genetic profile of HCM in Egypt.

  through study completion, at least once at the time of inclusion

• Study the basic mechanisms responsible for the HCM in Egypt

  To study different phenotypes at a molecular and cellular level including genotype-phenotype correlation.

  through study completion, at least once at the time of inclusion, or

Eligibility Criteria

• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Egyptian patients diagnosed with hypertrophic cardiomyopathy (either obstructive or non-obstructive), and their family members (either apparently healthy or not) who are willing to participate in this registry.

You may qualify if:

• All patients diagnosed with hypertrophic cardiomyopathy (index patients) who are willing and consented to participate in the registry.
• All family members of index patients who are willing and consented to participate in the registry.

You may not qualify if:

• Refusal to consent to participate in the registry program.

Sponsors & Collaborators

• Magdi Yacoub Heart Foundation: lead

Study Sites (1)

Aswan Heart Centre - Magdi Yacoub Heart Foundation

Aswān, Egypt

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Our biobank includes: * Blood samples for genetic analysis from all recruited patients and their family members. * Human specimens collected from hypertrophic cardiomyopathy patients after surgical intervention (extended septal myectomy).

MeSH Terms

Conditions

Cardiomyopathy, Hypertrophic; Cardiomyopathy, Hypertrophic, Familial

Condition Hierarchy (Ancestors)

Cardiomyopathies; Heart Diseases; Cardiovascular Diseases; Aortic Stenosis, Subvalvular; Aortic Valve Stenosis; Aortic Valve Disease; Heart Valve Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Magdi H Yacoub, FRS OM

CONTACT

m.yacoub@imperial.ac.uk

Shehab M Anwer, MBBCh., MRes

CONTACT

+41788816333; shehabanwer@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 14, 2022
• First Posted: June 1, 2023
• Study Start: January 1, 2014
• Primary Completion (Estimated): January 1, 2030
• Study Completion (Estimated): January 1, 2030
• Last Updated: June 1, 2023

Record last verified: 2023-05

Locations

EG (1)